UBS AM
IMGN

UBS AM’s Immunogen Inc IMGN Stock Holding History

UBS AM’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-310,789
Closed -$9.21M – 2584
2023
Q4 		$9.21M Buy
310,789
+4,769
+2% +$95K ﹤0.01% 1017
2023
Q3 		$4.86M Buy
306,020
+12,230
+4% +$203K ﹤0.01% 1213
2023
Q2 		$1.13M Hold
293,790
– – ﹤0.01% 1948
2023
Q1 		$1.13M Buy
293,790
+46,711
+19% +$199K ﹤0.01% 1948
2022
Q4 		$1.23M Buy
247,079
+2,477
+1% +$13.4K ﹤0.01% 1757
2022
Q3 		$1.17M Buy
244,602
+24,834
+11% +$131K ﹤0.01% 1875
2022
Q2 		$989K Buy
219,768
+32,642
+17% +$142K ﹤0.01% 1969
2022
Q1 		$891K Hold
187,126
– – ﹤0.01% 2201
2021
Q4 		$1.39M Buy
187,126
+26,993
+17% +$168K ﹤0.01% 2043
2021
Q3 		$908K Buy
160,133
+2,852
+2% +$16.5K ﹤0.01% 2217
2021
Q2 		$1.04M Buy
157,281
+11,886
+8% +$82.9K ﹤0.01% 2199
2021
Q1 		$1.18M Sell
145,395
-16,451
-10% -$134K ﹤0.01% 2011
2020
Q4 		$1.04M Hold
161,846
– – ﹤0.01% 1967
2020
Q3 		$583K Hold
161,846
– – ﹤0.01% 2071
2020
Q2 		$744K Buy
161,846
+11,611
+8% +$49.4K ﹤0.01% 1932
2020
Q1 		$512K Sell
150,235
-37,561
-20% -$164K ﹤0.01% 1973
2019
Q4 		$959K Buy
187,796
+38,036
+25% +$129K ﹤0.01% 1927
2019
Q3 		$362K Buy
149,760
+17,540
+13% +$46.6K ﹤0.01% 2393
2019
Q2 		$287K Hold
132,220
– – ﹤0.01% 2427
2019
Q1 		$358K Buy
132,220
+21,189
+19% +$91.8K ﹤0.01% 2241
2018
Q4 		$533K Buy
111,031
+16,821
+18% +$102K ﹤0.01% 1965
2018
Q3 		$892K Buy
94,210
+4,700
+5% +$45.2K ﹤0.01% 1854
2018
Q2 		$871K Buy
89,510
+6,900
+8% +$72.7K ﹤0.01% 1867
2018
Q1 		$869K Buy
82,610
+37,606
+84% +$371K ﹤0.01% 1836
2017
Q4 		$288K Sell
45,004
-5,235
-10% -$32.3K ﹤0.01% 2141
2017
Q3 		$384K Buy
50,239
+842
+2% +$5.59K ﹤0.01% 2015
2017
Q2 		$351K Sell
49,397
-18,700
-27% -$85.6K ﹤0.01% 1973
2017
Q1 		$264K Buy
68,097
+40,700
+149% +$119K ﹤0.01% 2058
2016
Q4 		$55K Sell
27,397
-39,200
-59% -$78.7K ﹤0.01% 2301
2016
Q3 		$178K Hold
66,597
– – ﹤0.01% 2489
2016
Q2 		$205K Hold
66,597
– – ﹤0.01% 2435
2016
Q1 		$568K Sell
66,597
-4,300
-6% -$36.4K ﹤0.01% 1861
2015
Q4 		$962K Buy
70,897
+2,200
+3% +$27.1K ﹤0.01% 1757
2015
Q3 		$660K Buy
68,697
+11,000
+19% +$161K ﹤0.01% 1878
2015
Q2 		$830K Sell
57,697
-1,300
-2% -$14.3K ﹤0.01% 1773
2015
Q1 		$528K Buy
58,997
+27,900
+90% +$202K ﹤0.01% 1950
2014
Q4 		$190K Hold
31,097
– – ﹤0.01% 2484
2014
Q3 		$329K Hold
31,097
– – ﹤0.01% 2100
2014
Q2 		$368K Hold
31,097
– – ﹤0.01% 2068
2014
Q1 		$464K Buy
31,097
+1,900
+7% +$30K ﹤0.01% 1940
2013
Q4 		$428K Sell
29,197
-900
-3% -$13.8K ﹤0.01% 1894
2013
Q3 		$512K Hold
30,097
– – ﹤0.01% 1768
2013
Q2 		$499K Buy
+30,097
New +$488K ﹤0.01% 1713

Other funds holding IMGN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

UBS AM's IMGN Position: Q1 2024 in Review

UBS AM sold out of Immunogen Inc (IMGN) in Q1 2024, closing a stake of 310,789 shares — an estimated $9.21M sold.

UBS AM first reported a position in IMGN in Q2 2013 and held it in 43 quarters. The position peaked at $9.21M in Q4 2023. 3 funds tracked by Wall St. Rank hold IMGN as of Q1 2024.

  • UBS AM reported no remaining Immunogen Inc position as of Q1 2024 after selling out during the quarter.
  • UBS AM sold 310,789 Immunogen Inc shares in Q1 2024, an estimated $9.21M.
  • UBS AM first reported a position in Immunogen Inc in Q2 2013 and held it in 43 quarters.
  • UBS AM's Immunogen Inc position peaked at $9.21M in Q4 2023.
  • 3 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2024.

Based on UBS AM's 13F filing for Q1 2024, filed 15 May 2024.